The company will evaluate the Hepzato kit as a combination therapy with the standard of care in patients with liver-dominant ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

Sweetman now had Stage 4 cancer and he soon learned that treating uveal melanoma liver metastases “was a little tricky.” ...

Glossop's Craig Shore, whose ocular uveal melanoma has mutated to his liver, has been informed the NHS cannot provide chemosaturation. The 52-year-old said he may need to raise at least £120,000 ...

HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of ...

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. The therapy ...

The treatment is approved for adults with metastatic uveal melanoma affecting the liver under specific conditions. In Europe, Delcath offers the HDS as the CHEMOSAT system, a Class III medical ...

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration ...

In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.